
    terminated due to low accrual.
  
['marginal zone lymphoma', 'recurrent marginal zone lymphoma', 'recurrent waldenstrom macroglobulinemia', 'refractory marginal zone lymphoma', 'refractory waldenstrom macroglobulinemia', 'waldenstrom macroglobulinemia']
['carfilzomib']

        Inclusion Criteria:

          -  Waldenstrom's macroglobulinemia (WM) or marginal zone lymphoma (MZL) based on
             institutional pathology review; patients may have either previously untreated or
             relapsed/refractory disease

          -  Measurable disease: for WM presence of monoclonal IgM immunoglobulin concentration on
             serum electrophoresis, with lymphoplasmacytic marrow infiltrate; for MZL: measurable
             nodal disease measuring at least 1.5 cm in longest dimension, or splenomegaly

          -  Indication for initiation of therapy

          -  Absolute neutrophil count (ANC) > 1,000/uL unless disease-related (due to marrow
             infiltration or splenomegaly)

          -  Platelet count > 75,000/uL unless disease-related (due to marrow infiltration or
             splenomegaly)

          -  Serum creatinine < 2.5 mg/dL or creatinine clearance > 30 cc/min

          -  Bilirubin < 2 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN

          -  All patients must be informed of the investigational nature of this study and have
             given written consent in accordance with institutional and federal guidelines

          -  Expected survival of > 90 days

          -  Females of childbearing potential (FCBP) must agree to pregnancy testing and to
             practice contraception

          -  Male subjects must agree to practice contraception

        Exclusion Criteria:

          -  Known human immunodeficiency virus (HIV), hepatitis C, or hepatitis B positivity
             (subjects with hepatitis B surface antigen [SAg] or core antibody positivity, who are
             receiving and responding to antiviral therapy directed at hepatitis B or are negative
             for hepatitis B virus [HBV] deoxyribonucleic acid [DNA], are allowed)

          -  Candidate for potentially curative antibiotic therapy for gastric mucosa-associated
             lymphoid tissue (MALT); (gastric MALT lymphoma patients with stage I/II helicobacter
             [H.] pylori positive lymphoma must fail therapy with H.-pylori directed therapy before
             being considered for this study)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher

          -  Known active central nervous system (CNS) involvement

          -  Pregnant or lactating females

          -  Inadequate cardiac function, as measured by left ventricular ejection fraction (LVEF)
             that is less than or equal to 40%, or the presence of New York Heart Association
             (NYHA) classification of greater than stage II congestive heart failure

          -  Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to
             screening

          -  Uncontrolled inter-current illness including, but not limited to, unstable angina,
             recent myocardial infarction within 6 months of screening and uncontrolled cardiac
             arrhythmias, psychiatric illness, or psychosocial difficulty that would limit
             compliance with study requirements

          -  Non-hematologic malignancy within the past 3 years with the exception of a) adequately
             treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b)
             carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason grade 6 or
             less with stable prostate-specific antigen levels; or d) cancer considered cured by
             surgical resection or unlikely to impact survival during the duration of the study
      